Products - Oesophageal cancer | Topic | NICE

Showing 6 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zanidatamab in combination for untreated HER2-positive unresectable advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma [ID6672]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sonesitatug vedotin for previously treated metastatic claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinomar [ID6669]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC